Antibody-mediated blockade of the PD-1/PD-L1 pathway has successfully treated a subset of patients with advanced cancers, such as melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and head and neck squamous cell carcinoma, and has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of various cancers (15, 16). Here, CD274 is linked to cancer.